<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370145</url>
  </required_header>
  <id_info>
    <org_study_id>JXFeng</org_study_id>
    <nct_id>NCT04370145</nct_id>
  </id_info>
  <brief_title>Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy</brief_title>
  <official_title>Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Application of multi-center, prospective study on the severity of postoperative cholangitis
      biliary atresia classification, according to the degree of cholangitis targeted therapy, to
      improve the therapeutic effect of postoperative cholangitis biliary atresia, decrease the
      overuse of antibiotics related complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cholangitis patients post-kasai Portoenterostomy were grouped by cholangitis severity score,
      according to the severity was divided into mild, moderate, severe cholangitis, all levels of
      cholangitis patients were divided into subgroups by age and post-kasai Portoenterostomy
      jaundice matching design of experiment, then they were randomly divided into control group
      and experimental group, and all the control group unified antibiotic treatment, the
      experimental group was graded antibiotic treatment according to the severity cholangitis,
      after three days treatment，evaluate each treatment effect, average hospitalization days, the
      average hospitalization expenses, antimicrobial drug use strength to evaluate the therapeutic
      effect of postoperative cholangitis biliary atresia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cholangitis patients post-kasai Portoenterostomy were grouped by cholangitis severity score, according to the severity was divided into mild, moderate, severe cholangitis, all levels of cholangitis patients were divided into subgroups by age and post-kasai Portoenterostomy jaundice matching design of experiment, then they were randomly divided into control group and experimental group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery rate</measure>
    <time_frame>7 days</time_frame>
    <description>The cure indicator including:1.Temperature:T≤37.5℃; 2. Infection index:WBC＜10x109/L, CRP＜10mg/L. After 7days treatment, we calculate the cure number and recovery rate of each group to evaluate the efficiency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>1 year</time_frame>
    <description>To collect recurrent episode of cholangitis and recurrent rate of each group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cholangitis, Secondary Biliary</condition>
  <condition>Treatment Compliance</condition>
  <condition>Antibodies Drug Specific</condition>
  <arm_group>
    <arm_group_label>moderate cholangitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meropenem injection, iv. drip,20mg/Kg，Q12h; Tinidazole injection, iv. drip,20mg/Kg,Qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>severe cholangitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meropenem injection, iv. drip,20mg/Kg，Q8h; Teicoplanin injection, iv. drip,10mg/Kg,Qd; Tinidazole injection, iv. drip,20mg/Kg,Qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulperazon, iv.,drip,100mg/Kg,Bid; Tinidazole injection, iv. drip,20mg/Kg,Qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulperazon</intervention_name>
    <description>moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.</description>
    <arm_group_label>moderate cholangitis</arm_group_label>
    <other_name>Tinidazole injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teicoplanin</intervention_name>
    <description>severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.</description>
    <arm_group_label>severe cholangitis</arm_group_label>
    <other_name>Meropenem Injection</other_name>
    <other_name>Tinidazole injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem Injection</intervention_name>
    <description>cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>Tinidazole injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 3 months to 2 years old, gender is not limited.

          2. Patients with cholangitis post-kasai Portoenterostomy.

          3. No other treatment before entering the group.

          4. The patient must sign an informed consent form and can actively cooperate with the
             treatment and follow-up.

        Exclusion Criteria:

          1. Patients with other infectious lesions.

          2. Patients with other severe deformity.

          3. Patients with end-stage liver failure.

          4. Patientsn with liver transplantation.

          5. Patients with mental symptoms or other disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Jiexiong, Postdoctoral</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Jiexiong, Postdoctoral</last_name>
    <phone>18607187276</phone>
    <phone_ext>86-</phone_ext>
    <email>wangpeipeggy@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang Jixin, Doctor</last_name>
    <phone>15927121656</phone>
    <phone_ext>86-</phone_ext>
    <email>yangjixin0910@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji hospital affiliated to tongji medical college of huazhong university of science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Feng Jiexiong, Postdoctoral</last_name>
      <phone>18607187276</phone>
      <phone_ext>86-</phone_ext>
      <email>wangpeipeggy@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yang Jixin, Doctor</last_name>
      <phone>15927121656</phone>
      <phone_ext>86-</phone_ext>
      <email>yangjixin0910@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TongjiHospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Feng Jiexiong, Postdoctoral</last_name>
      <phone>18607187276</phone>
      <phone_ext>86-</phone_ext>
      <email>wangpeipeggy@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yang Jixin, Doctor</last_name>
      <phone>15927121656</phone>
      <phone_ext>86-</phone_ext>
      <email>yangjixin0910@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>J.X. Feng</investigator_full_name>
    <investigator_title>Chief in Department</investigator_title>
  </responsible_party>
  <keyword>Cholangitis</keyword>
  <keyword>biliary atresia</keyword>
  <keyword>kasai Portoenterostomy</keyword>
  <keyword>antibiotics</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
    <mesh_term>Sulperazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

